SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is under pressure after its outlook highlighted third-party data-center capacity delays, shifting planned activations and revenue recognition and raising concerns about execution and capital spending. Traders also cite analyst target cuts and weakness across AI and neocloud stocks, while bulls argue demand remains strong and view the selloff as a buying opportunity.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Jensen Huangs reported departure has intensified a sharp selloff, with traders debating whether leadership uncertainty and scrutiny of alleged chip diversions to China could hurt Nvidias business and reputation. Some expect more downside pending answers and a permanent succession plan, while others view the reaction as overdone and say AI demand and the companys fundamentals remain intact; earnings are the next focus.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

A widespread Microsoft 365 outage disrupting Outlook, Teams, Copilot and other services is the main catalyst, prompting concern about Microsofts reliability and possible customer or SLA fallout; cyberattack claims remain speculation, with Microsoft reporting no evidence of malicious activity. Traders debate whether the disruption warrants more downside or is a temporary setback, while others point to the stocks relative resilience and view the dip as a buying opportunity.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

China-related scrutiny and allegations about Webulls ties and disclosures are widely blamed by traders for the stocks sharp decline, though some argue the concerns are overstated and point to the companys growth and profitability. The community is also positioning around Q3 earnings, with debate between further downside and a possible recovery if results are strong.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs steep pullback is prompting debate over whether traders are taking profits after a rapid rally on the Nvidia leadership turmoil, or whether the move signals broader doubts about AI spending and chip-sector valuations. Some still see AMD benefiting as an Nvidia alternative, while others argue that a weakening AI-capex trade could pressure the whole sector.

Applied Materials, Inc. engages in provision of materials engineering solutions used to produce semiconductors. The firm also focuses on design, development, production, and servicing of the critical wafer fabrication tools used for customers to manufacture semiconductors. It operates through the following segments: Semiconductor Systems and Applied Global Services (AGS). The Semiconductor Systems segment includes designing, development, manufacturing and sale of equipment used to fabricate semiconductor chips referred to as integrated circuits. The AGS segment engages in provision of services, spares, and factory automation software to customer fabrication plants globally. The company was founded on November 10, 1967 and is headquartered in Santa Clara, CA.

Applied Materials Inc.

Applied Materials better-than-expected quarter and higher outlook have not prevented a sharp pullback, as traders point to semiconductor-equipment valuation pressure and broader chip-sector selling rather than weak company results. The debate is between a sell-the-news/sector repricing and the view that AI-driven equipment demand and fundamentals remain strong.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavaxs quarterly update and higher full-year revenue outlook, supported by a Sanofi milestone, are drawing attention, but traders are weighing that progress against the delayed profitability timeline and a share-price decline amid a broader market selloff. Some see the Sanofi and Pfizer partnerships as validation of the Matrix-M strategy, while critics say execution and recurring revenue remain unproven.

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in São Paulo, Brazil.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Nu Holdings strong third-quarter results, including revenue and profit growth, are driving a sharp rally, with traders praising the performance and expansion in Mexico. Debate centers on rising loan delinquencies and whether the earnings strength can sustain the rebound.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Ciscos earnings beat and raised outlook have been overshadowed by a share-price selloff, as traders focus on lower gross margins from hardware mix and memory costs, along with concerns about slowing growth and product orders. Some see the reaction as an overdone pullback given AI-networking demand, while others point to broader tech-market volatility.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

The CHMP reaffirmed its recommendation to refuse EU marketing authorization for MIPLYFFA, citing insufficient evidence of efficacy, driving a sharp selloff. Traders largely describe the setback as expected and point to the U.S.-approved business as a continuing support, while others see a meaningful loss of European upside and renew calls for a company sale.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts Think Oculis Holding AG (OCS) Could Surge 384.89%: Read This Before Placing a Bet

The mean of analysts' price targets for Oculis Holding AG (OCS) points to a 384.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Down 21.1% in 4 Weeks, Here's Why Oculis Holding AG (OCS) Looks Ripe for a Turnaround 

The heavy selling pressure might have exhausted for Oculis Holding AG (OCS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Oculis Holding AG (OCS) Reports Q3 Loss, Lags Revenue Estimates

Oculis Holding AG (OCS) delivered earnings and revenue surprises of +24.49% and -96.93%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Oculis Holding AG (OCS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Oculis Holding AG (OCS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

After Plunging 24% in 4 Weeks, Here's Why the Trend Might Reverse for Oculis Holding AG (OCS)

Oculis Holding AG (OCS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength?

Halozyme Therapeutics (HALO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Wall Street Analysts Believe Oculis Holding AG (OCS) Could Rally 199.75%: Here's is How to Trade

The mean of analysts' price targets for Oculis Holding AG (OCS) points to a 199.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does Oculis Holding AG (OCS) Have the Potential to Rally 187.83% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 187.8% in Oculis Holding AG (OCS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Oculis Holding AG (OCS) Reports Q2 Loss, Tops Revenue Estimates

Oculis Holding AG (OCS) delivered earnings and revenue surprises of +58.33% and +49.05%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Vertex Pharmaceuticals (VRTX) Q2 Earnings Lag Estimates

Vertex (VRTX) delivered earnings and revenue surprises of -1.25% and +3.32%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The firm's pipeline includes multiple product candidates in development such as, OCS-01, a topical retinal candidate for diabetic macular edema, OCS-02, a topical biologic candidate for dry eye disease, and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company was founded in 2016 and is headquartered in Zug, Switzerland.

Oculis Holding AG

OCS Stock Drops Over 23% — Eye Drop Trial For Diabetic Vision Loss Misses Target

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>OCS-01 failed to meet the primary endpoint of improving visual acuity in both Phase 3 DIAMOND studies.</li><li>The treatment reduced retinal thickness versus placebo, but those benefits did not translate into better vision outcomes.</li><li>Oculis plans to shift resources toward its optic neuropathy and dry eye disease programs.</li></ul><p>Shares of Oculis Holding (OCS) fell more than 23% during Friday afternoon trading after the company reported topline results from its Phase 3 DIAMOND-1 and DIAMOND-2 trials of OCS-01 eye drops in patients with diabetic macular edema (DME).</p><p>The company said the primary endpoint of the Phase 3 studies was not met.</p><p>At the time of writing, OCS shares were down 23.42%.</p><h2 class="st-heading-2">Primary Goal Not Met In OCS Eye Drop Trials</h2><p>The DIAMOND program included two Phase 3 clinical trials testing OCS-01 eye drops in patients with diabetic macular edema (DME) over 52 weeks. More than 800 patients were enrolled across 119 study sites in the&nbsp;U.S. and other countries.</p><p>The main goal of the trials, which was to improve vision as measured by best corrected visual acuity, was not met in either study.</p><p>However, the treatment did show a clear benefit on a secondary measure, with OCS-01 reducing retinal thickness compared to the placebo group across both trials.&nbsp;</p><h2 class="st-heading-2">OCS Shifts Focus After Dropping FDA Filing Plans</h2><p>Based on the trial results, Oculis said it will not move forward with an FDA filing for OCS-01 in diabetic macular edema at this time.</p><p>Riad Sherif, M.D., Chief Executive Officer of Oculis, said, “We are naturally disappointed that the substantial and sustained reduction in retinal thickness observed across both trials didn’t translate into BCVA improvement at week 52.”</p><p>Now, the company will redirect its focus and resources to other late-stage programs, including the Privosegtor PIONEER trial for optic neuropathies and the Licaminlimab PREDICT-1 study in dry eye disease.</p><h2 class="st-heading-2">What Retail Sentiment Says About OCS Stock</h2><p>Stocktwits sentiment on OCS was “bullish” on Friday, unchanged in the past 24 hours. Message volume was “normal.”</p><p>OCS shares have gained 18% in the past 12 months.&nbsp;</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

Azitra Inc, a micro-cap dermatology company, was among the top trending stocks on Stocktwits on Wednesday.

Shares of OCS fell more than 23% after the company reported topline results from its Phase 3 DIAMOND-1 and DIAMOND-2 trials of OCS-01 eye drops in patients with diabetic macular edema.

Oculis said it will not pursue US Food and Drug Administration (FDA) filing for OCS-01 in diabetic macular edema following disappointing late-stage trial results.

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$7.42
Prev Close	$7.50
Open	$7.51
Dividend Yield	0.00%
50-Day Moving Average	$8.83
Beta	0.65
Avg. Volume	332,022.20
PE Ratio	-4.36

52-Week High	$34.48
52-Week Low	$6.78
Market Capitalization	$462.99M
EPS (Annual)	-$2.28
Price to Book	1.86
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

OCS Fundamentals